Biogen Announces FDA Approval of Plegridy (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
The Pharma Data
FEBRUARY 1, 2021
Plegridy is a proven, effective therapy for relapsing MS, and this approval gives new and current MS patients a different delivery method that has the potential to significantly reduce injection site reactions.”. A list of adverse events can be found in the full Plegridy product labeling for each country where it is approved.
Let's personalize your content